Celldex Therapeutics (NASDAQ:CLDX) Coverage Initiated at The Goldman Sachs Group

Equities research analysts at The Goldman Sachs Group assumed coverage on shares of Celldex Therapeutics (NASDAQ:CLDX) in a research note issued to investors on Monday, Marketbeat.com reports. The brokerage set a “neutral” rating and a $45.00 price target on the biopharmaceutical company’s stock. The Goldman Sachs Group’s target price suggests a potential upside of 38.89% from the company’s current price.

Other equities analysts have also issued research reports about the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $67.00 price objective on shares of Celldex Therapeutics in a report on Monday, September 16th. Stifel Nicolaus started coverage on shares of Celldex Therapeutics in a report on Tuesday, June 18th. They set a “buy” rating and a $58.00 price objective on the stock. Wolfe Research lowered shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a report on Friday, September 27th. Wells Fargo & Company upgraded shares of Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 26th. Finally, HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a report on Thursday, September 26th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $61.14.

Celldex Therapeutics Trading Down 4.7 %

Shares of CLDX opened at $32.40 on Monday. The firm’s fifty day simple moving average is $38.30 and its two-hundred day simple moving average is $38.18. Celldex Therapeutics has a 12 month low of $22.11 and a 12 month high of $53.18. The stock has a market capitalization of $2.15 billion, a P/E ratio of -11.37 and a beta of 1.56.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.05. Celldex Therapeutics had a negative net margin of 1,809.18% and a negative return on equity of 23.66%. The firm had revenue of $2.50 million for the quarter, compared to analyst estimates of $1.13 million. As a group, research analysts predict that Celldex Therapeutics will post -2.5 EPS for the current fiscal year.

Institutional Investors Weigh In On Celldex Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. bought a new stake in Celldex Therapeutics in the 2nd quarter worth about $76,000. Headlands Technologies LLC bought a new stake in Celldex Therapeutics in the 1st quarter worth about $147,000. CANADA LIFE ASSURANCE Co grew its position in Celldex Therapeutics by 26.4% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock worth $192,000 after purchasing an additional 955 shares in the last quarter. Ameritas Investment Partners Inc. grew its position in Celldex Therapeutics by 34.3% in the 1st quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company’s stock worth $260,000 after purchasing an additional 1,582 shares in the last quarter. Finally, Quest Partners LLC grew its position in Celldex Therapeutics by 1,364.9% in the 2nd quarter. Quest Partners LLC now owns 7,383 shares of the biopharmaceutical company’s stock worth $273,000 after purchasing an additional 6,879 shares in the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.